Aegerion Pharmaceuticals Observes World Lipodystrophy Day
31.3.2016 09:00 | NASDAQ OMX
CAMBRIDGE, Mass., 2016-03-31 09:00 CEST (GLOBE NEWSWIRE) --
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its observance of World Lipodystrophy Day.
Chief Executive Officer Mary Szela said, "We support the Association of Families Affected by Lipodystrophies in Spain, Europe & Latin America (AELIP), Lipodystrophy United (LU), and others in the lipodystrophy community in their objective to increase awareness and diagnosis of this serious and often undiagnosed rare disease. Education is an important step towards making an impact for people affected by lipodystrophy.”
Lipodystrophy is a group of rare diseases characterized by the lack of fat tissue. In some patients, it is genetic, and in others it may be acquired. It can be characterized by a widespread lack of fat tissue under the skin (generalized lipodystrophy) or limited lack of fat tissue (partial lipodystrophy). This loss of fat tissue might cause a deficit in the hormone leptin leading to multiple medical complications such as severe metabolic complications.
“Lipodystrophies are rare diseases, meaning they can be difficult to diagnose correctly and therefore treat properly and efficiently,” said David Araújo-Vilar, MD, Professor of Medicine, Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela (Spain). “A common feature of most lipodystrophies is the predisposition to diabetes mellitus, dyslipidemia and cardiovascular diseases. Through increased awareness and education, physicians can more accurately diagnose and effectively treat these serious diseases.”
“Our objectives for World Lipodystrophy Day include raising awareness of the public health problem posed by lipodystrophy, implementing actions that impact the challenges faced by patients with lipodystrophy and their families, and joining together with the community to pool resources and improve care for those affected by this rare disease,” said Naca Pérez de Tudela, president of AELIP.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating, rare diseases. For more information about the company, please visit www.aegerion.com.
Aegerion Pharmaceuticals, Inc.
Associate Director, Investor & Public Relations
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Novavax' Preclinical Influenza Nanoparticle Study Published in Vaccine23.8.2017 13:00 | Pressemelding
Novel vaccine candidate, NanoFlu(TM), outperforms market-leading Fluzone® High Dose based on antibody titers and neutralization of recent and historic influenza viruses in a preclinical study GAITHERSBURG, Md., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced that data from a preclinical study of its nanoparticle influenza vaccine candidate with its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) have been published in the journal Vaccine. Novavax is developing NanoFlu to protect older adults from seasonal influenza. The manuscript describes the formulation of Novavax' novel seasonal influenza vaccine candidate, NanoFlu, based on the 2017-2018 World Health Organization (WHO) recommended influenza strains. The study, conducted in ferrets, found that NanoFlu induced hemagglutination-inhibition (HAI) and microneutralizing (MN) antibodies against a broad range of influenza subtypes. In a head-to-head comparison against standard-dose and high-do
Crown Bioscience Names Dr. Leon Hall Vice President of Global Scientific Excellence23.8.2017 12:29 | Pressemelding
SANTA CLARA, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence. In his new role, Dr. Hall will be responsible for overseeing global R&D programs and advancing Crown Bioscience's scientific excellence initiatives. "Leon's appointment reinforces Crown Bioscience's dedication to innovation and commitment to providing the highest quality therapeutic technology services," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global
Blackbird Energy Inc. annonserer utnevnelsen av Allan Dixon som sjef for bedriftsutvikling23.8.2017 12:02 | Pressemelding
CALGARY, Alberta, 23. aug. 2017 (GLOBE NEWSWIRE) - Blackbird Energy Inc. (TSX-V:BBI) («Blackbird») har gleden av å kunngjøre utnevnelsen av Allan Dixon som sjef for bedriftsutvikling. I denne rollen vil Dixon være ansvarlig for investorrelasjoner, kommunikasjonsinitiativer og strategiske bedriftsbevissthetsprogrammer i Nord-Amerika og Europa. Dixon har en omfattende bakgrunn i Calgarys olje- og gassindustri med erfaring fra investorrelasjoner ved Birchcliff Energy Ltd., aksjeanalyse ved National Bank Financial og investeringsrelatert bankvirksomhet ved Tristone Capital. Dixon har en bachelorgrad i handelsfag med spesialisering innen finans fra Dalhousie University. «Jeg er veldig glad for å ønske Allan velkommen til Blackbird-teamet, og jeg ser frem til å jobbe med ham. Med sin varierte bakgrunn og erfaring med å jobbe med noen av verdens fremste innovatører i bransjen, har jeg den største tillit til at han vil være et verdifullt tilskudd til teamet vårt og en ressurs fo
International Body Positive Mentor, Arabella S. Ruby, Launches New Fashion Collection Under the Xehar Brand, Arabella by Xehar23.8.2017 12:00 | Pressemelding
Xehar's successful ambassador marketing campaign continues to drive online sales while spreading body positive messages among millennials around the world PLAYA VISTA, Calif., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Today Xehar launches their newest collection Arabella by Xehar, an edgy and contemporary plus size fashion line targeting progressive millennials. High demand for Xehar's custom clothing lines can be seen by the recent collection Laura by Xehar, which sold out in a record 10 days. Xehar has developed a proven method in creating collections inspired by Body Positive Mentors who have a significant social media following. A photo is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/10d6e5d8-c740-4c41-aa56-2255e6f70ad9 "Customers appreciate authenticity, and we are seeing great results by sharing our products through our Body Positive Mentors," says Hadari Oshri, CEO and founder of Xehar. "We are actively searching for m
Nasdaq Offers Proprietary U.S. Equity Data Feeds from Equinix Data Center in London23.8.2017 09:11 | Pressemelding
NEW YORK and LONDON, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) has announced the availability of proprietary U.S. equity feeds from Equinix's London International Business Exchange(TM) (IBX®) data center - LD4 - located in Slough, U.K. As part of Nasdaq's efforts to bring U.S proprietary equities data to a larger audience, Nasdaq now offers Nasdaq TotalView and Nasdaq Basic from LD4. Nasdaq Basic combines Nasdaq Best Bid and Offer (QBBO), with either Nasdaq Last Sale (NLS), or Nasdaq Last Sale Plus (NLS Plus). "We continue to focus on working closely with our clients around the world in order to help them gain secure, efficient access to our markets," said Jeff Kimsey, Head of Global Data Products, Nasdaq. "Buy-and sell-side clients based in the U.K. can now access our U.S. data products directly from the exchange through the Equinix LD4 data center." This new Point of Presence (PoP) will allow firms direct access to U.S. mar
Real People Investment Holdings Limited: Nordic bondholders approved an extension of the standstill period in written procedure22.8.2017 20:47 | Pressemelding
Real People Investment Holdings Limited (the "Company") today announces the successful completion of a written procedure in relation to the Company's outstanding SEK 260,000,000 and NOK 135,000,000 senior unsecured callable bonds with ISINs SE0005392560 and NO0010689342 2013/2018. The Nordic bondholders authorized the bondholders' agent to (i) consent to an extension of the last date of the Standstill Period (as defined in the Standstill Agreement referred to below) from no later than 31 August 2017 until no later than 30 November 2017, and (ii) approve that an addendum is made to the Standstill Agreement to the effect that the automatic termination of the Standstill Period upon certain events is qualified by the requirement that the Majority Standstill Creditors (as defined in the Standstill Agreement) also elects to terminate the Standstill Period (the "Proposal"). As previously communicated in press releases, the Real People Group is experiencing f
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom